Auris closes $220M in new financing to advance robotic technology: 4 notes

Auris Health received $220 million in equity financing to advance the commercialization of its endobronchial Monarch Platform and robotic technology development.

Advertisement

Here are four notes:

1. Led by Partner Fund Management, Auris received additional funding from new investors Wellington Management, D1 Capital Partners and Senator Investment Group.

2. Existing Auris investors who participated in the finance round included Mithril Capital, Lux Capital and Viking Global Investors.

3. Designed for diagnostic and therapeutic bronchoscopic procedures, the Monarch Platform uses a computer-assisted controller interface to navigate a flexible robotic endoscope to the periphery of the lung.

4. Auris has raised more than $700 million to date.

More articles on devices and implants:
Paradigm Spine’s coflex device receives additional payer policy coverage: 3 notes
Device company allegedly sold spinal implants that decayed in patients: 6 insights
Medicrea closes $30M refinancing deal to boost AI, implant production: 4 highlights

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.